Evaluating a new treatment for early Alzheimer's disease
A Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's Disease
This study is testing a new medication called PQ 912 to see if it can help people with early Alzheimer's disease by slowing down its progression, and it’s looking for participants who want to help find out if this treatment works better than a placebo.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10549805 on NIH RePORTER |
What this research studies
This research investigates the efficacy and safety of PQ 912, a novel small molecule designed to treat early Alzheimer's disease by inhibiting specific enzymes linked to the disease's progression. The trial will involve a randomized, double-blind, placebo-controlled approach, meaning that participants will be assigned to receive either the treatment or a placebo without knowing which one they have received. The study aims to measure the treatment's effects on biomarkers and cognitive functions, providing valuable insights into its potential benefits for patients. Participants will be monitored closely throughout the trial to assess any changes in their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early Alzheimer's disease who meet specific inclusion criteria.
Not a fit: Patients with advanced Alzheimer's disease or those not meeting the study's eligibility criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that slows the progression of early Alzheimer's disease and improves cognitive function.
How similar studies have performed: Previous research has shown promise with similar approaches targeting the mechanisms of Alzheimer's disease, indicating potential for success in this trial.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Feldman, Howard — University of California, San Diego
- Study coordinator: Feldman, Howard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.